Loss of Heterozygosis on IFN-α Locus is a Prognostic Indicator of Bacillus Calmette-Guerin Response for Nonmuscle Invasive Bladder Cancer

Journal of Urology

Volumn 183, Issue 5, 2010, Pages 1738-1743

  Cai, Tommaso ^a   Nesi, Gabriella ^a   Dal Canto, Maurizio ^a   Tinacci, Galliano ^b   Mondaini, Nicola ^a   Piazzini, Mauro ^a   Geppetti, Pierangelo ^a   Bartoletti, Riccardo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

carcinoma; interferon alpha; loss of heterozygosity; Mycobacterium bovis; urinary bladder

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER RECURRENCE; CHROMOSOME 9P; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; FEMALE; FOLLOW UP; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; PRIORITY JOURNAL; PROGNOSIS; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRAVESICAL; AGED; BCG VACCINE; COMBINED MODALITY THERAPY; GENOTYPE; HUMANS; INTERFERON-ALPHA; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; URINARY BLADDER NEOPLASMS;

EID: 77950517366     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.12.105     Document Type: Article

References (25)

1. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466
2. Martínez-Piñeiro J.A., Martínez-Piñeiro L., Solsona E., et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?. Results of a prospective randomized trial. J Urol 174 (2005) 1242
3. Punnen S.P., Chin J.L., and Jewett M.A. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and interferon combination therapy. Can J Urol 10 (2003) 1790
4. Kim J.C., and Steinberg G.D. Medical management of patients with refractory carcinoma in situ of the bladder. Drugs Aging 18 (2001) 335
5. Herr H.W., Wartinger D.D., Fair W.R., et al. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year follow-up. J Urol 147 (1992) 1020
6. Esuvaranathan K., Chiong E., Thamboo T.P., et al. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 109 (2007) 1097
7. Witjes J.A. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 49 (2006) 790
8. Huguet J., Crego M., Sabate S., et al. Cystectomy in patients with high risk superficial bladder tumours who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 48 (2005) 53
9. Ahirwar D., Kesarwani P., Manchanda P.K., et al. Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guerin immunotherapy in bladder cancer. Cancer Genet Cytogenet 184 (2008) 1
10. O'Donnell M.A., Lilli K., and Leopold C. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172 (2004) 888
11. Suttman H., Jacobsen M., Reiss K., et al. Mechanism of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol 172 (2004) 1490
12. Oosterlinck W., Lobel B., Jakse G., et al. Guidelines on bladder cancer. Eur Urol 41 (2002) 105
13. Herr H.W., and Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 169 (2003) 1706
14. Schmidbauer J., and Lindenau G. Follow-up of nonmuscle invasive transitional cell carcinoma of the bladder: how and how often?. Curr Opin Urol 18 (2008) 504
15. Bartoletti R., Cai T., Dal Canto M., et al. Multiplex polymerase chain reaction in microsatellite analysis urine sediment cells. A fast and cheap method in diagnosing and monitoring of superficial transitional bladder cell carcinoma. J Urol 175 (2006) 2032
16. Bartoletti R., Dal Canto M., Cai T., et al. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment. Oncol Rep 13 (2005) 531
17. Lamm D.L., Crawford E.D., Blumenstein B., et al. Maintenance BCG immunotherapy for recurrent Ta, T1 and Tis transitional cell carcinoma of the bladder: a randomized prospective Southwest Oncology Group study. J Urol 163 (2000) 1124
18. Saint F., Salomon L., Quintela R., et al. Do prognostic parameters of remission versus relapse after bacillus Calmette-Guérin (BCG) immunotherapy exist?. Analysis of a quarter century of literature. Eur Urol 43 (2003) 351
19. Thalmann G.N., Sermier A., Rentsch C., et al. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 164 (2000) 2129
20. Slaton J.W., Karashima T., Perrotte P., et al. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res 7 (2001) 2840
21. Liu W., O'Donnell M.A., Chen X., et al. Recombinant bacillus Calmette-Guerin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. Cancer Immunol Immunother 58 (2009) 1647
22. Bilen C.Y., Inci K., Erkan I., et al. The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin. J Urol 169 (2003) 1702
23. Martínez-Piñeiro J.A., Flores N., Isorna S., et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89 (2002) 671
24. Okamura T., Tizawa K., Yamada Y., et al. Clinicopathologic evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer. J Urol 156 (1996) 967
25. Kaempfer R., Gerez L., Farbstein H., et al. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 14 (1996) 1778